Teprotumumab: First Approval
Any type of resource available online.
Teprotumumab (teprotumumab-trbw; TEPEZZATM – Horizon Therapeutics) is a monoclonal antibody insulin-like growth factor-I receptor (IGF-IR) antagonist developed for the treatment of thyroid eye disease (Graves ophthalmopathy/orbitopathy, thyroid-associated opthamology). Based on positive results from two multinational clinical trials teprotumumab was recently approved for this indication in the US. This article summarizes the milestones in the development of teprotumumab leading to this first approval for thyroid eye disease.
© Springer Nature Switzerland AG 2020